Skip to main content
NewslettersWatchlist

Biocryst Pharma Inc(BCRX-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low6.22
Day High6.56
Open:6.43
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Motley Fool
Why BioCryst Pharmaceuticals Vaulted Nearly 20% Higher on Monday
Motley Fool
BioCryst Pharmaceuticals (BCRX) Q1 2024 Earnings Call Transcript
Motley Fool
BioCryst Pharmaceuticals (BCRX) Q4 2023 Earnings Call Transcript
Motley Fool
BioCryst Pharmaceuticals (BCRX) Q3 2023 Earnings Call Transcript
GlobeNewswire
INESSS Recommends Public Reimbursement for BioCryst’s ORLADEYO® (berotralstat) for the Prevention of Attacks for Hereditary Angioedema Patients in Québec
Motley Fool
3 Magnificent Growth Stocks to Buy on the Dip
Motley Fool
BioCryst Pharmaceuticals (BCRX) Q2 2023 Earnings Call Transcript
Motley Fool
BioCryst Pharmaceuticals (BCRX) Q1 2023 Earnings Call Transcript
Motley Fool
Why BioCryst Pharmaceuticals Stock Is Soaring Today
Motley Fool
Why Shares of BioCryst Pharmaceuticals Jumped Today
Motley Fool
Why BioCryst Pharmaceuticals Stock Is Sinking Today
Motley Fool
BioCryst Pharmaceuticals (BCRX) Q4 2022 Earnings Call Transcript
Motley Fool
BioCryst Pharmaceuticals (BCRX) Q3 2022 Earnings Call Transcript
Motley Fool
Got $3,000? Here Are 2 Stocks That Will Make You Richer
Motley Fool
BioCryst Pharmaceuticals (BCRX) Q2 2022 Earnings Call Transcript
Motley Fool
Why BioCryst Pharmaceuticals Stock Is Bolting Higher Today
Globe Newswire
BioCryst Reports Second Quarter 2022 Financial Results and Upcoming Key Milestones
Globe Newswire
BioCryst Resumes Enrollment in BCX9930 Clinical Program
Motley Fool
3 Fast-Growing Stocks to Buy Now
Globe Newswire
BioCryst to Report Second Quarter 2022 Financial Results on August 4
Motley Fool
2 Biotech Stocks You'll Regret Not Buying on the Dip
Globe Newswire
BioCryst to Present at Upcoming Investor Conference
TipRanks
Analysts Conflicted on These Healthcare Names: ACADIA Pharmaceuticals (ACAD), BioCryst (BCRX) and Cigna (CI)
Globe Newswire
BioCryst Presents New Data Demonstrating Consistently Low Attack Rates Among HAE Patients After Switching to ORLADEYO® (berotralstat)
Globe Newswire
BioCryst Announces ORLADEYO® (berotralstat) Data to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2022
Globe Newswire
BioCryst Selects Pint Pharma as Commercial Partner for ORLADEYO® (berotralstat) in Latin America
Motley Fool
Why BioCryst Pharmaceuticals Topped the Market Today
Globe Newswire
FDA Grants Fast Track Designation for BioCryst’s ALK-2 Inhibitor, BCX9250
Globe Newswire
BioCryst Announces Health Canada has Authorized ORLADEYO® (berotralstat), the Only Oral Treatment for the Prevention of Hereditary Angioedema Attacks
Globe Newswire
BioCryst to Present at Upcoming Investor Conferences
Globe Newswire
BioCryst to Present at Upcoming Investor Conferences
Motley Fool
Why BioCryst Stock Lost Nearly 4% of Its Value Today

Profile

BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections. The company is advancing multiple internal programs toward potential commercialization including Fodosine in oncology, BCX-4208 in transplantation and autoimmune diseases and peramivir in seasonal and life threatening influenza. BioCryst has a worldwide partnership with Roche for the development and commercialization BCX-4208, and is collaborating with Mundipharma for the development and commercialization of Fodosine in markets across Europe, Asia, Australia and certain neighboring countries.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.